Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer

The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosyl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Salatino, M., Girotti, M.R., Rabinovich, G.A.
Formato: JOUR
Materias:
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_15356108_v33_n2_p155_Salatino
Aporte de:
id todo:paper_15356108_v33_n2_p155_Salatino
record_format dspace
spelling todo:paper_15356108_v33_n2_p155_Salatino2023-10-03T16:21:43Z Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer Salatino, M. Girotti, M.R. Rabinovich, G.A. asparagine linked oligosaccharide epidermal growth factor glycan glycogen synthase kinase transcription factor 4 polysaccharide programmed death 1 ligand 1 cancer immunotherapy cytotoxicity ectopic expression endocytosis glycosylation human immunosuppressive treatment lysosome nonhuman priority journal protein protein interaction Short Survey treatment response triple negative breast cancer tumor microenvironment tumor rejection upregulation immunotherapy B7-H1 Antigen Humans Immunotherapy Polysaccharides Triple Negative Breast Neoplasms The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. © 2018 Elsevier Inc. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_15356108_v33_n2_p155_Salatino
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic asparagine linked oligosaccharide
epidermal growth factor
glycan
glycogen synthase kinase
transcription factor 4
polysaccharide
programmed death 1 ligand 1
cancer immunotherapy
cytotoxicity
ectopic expression
endocytosis
glycosylation
human
immunosuppressive treatment
lysosome
nonhuman
priority journal
protein protein interaction
Short Survey
treatment response
triple negative breast cancer
tumor microenvironment
tumor rejection
upregulation
immunotherapy
B7-H1 Antigen
Humans
Immunotherapy
Polysaccharides
Triple Negative Breast Neoplasms
spellingShingle asparagine linked oligosaccharide
epidermal growth factor
glycan
glycogen synthase kinase
transcription factor 4
polysaccharide
programmed death 1 ligand 1
cancer immunotherapy
cytotoxicity
ectopic expression
endocytosis
glycosylation
human
immunosuppressive treatment
lysosome
nonhuman
priority journal
protein protein interaction
Short Survey
treatment response
triple negative breast cancer
tumor microenvironment
tumor rejection
upregulation
immunotherapy
B7-H1 Antigen
Humans
Immunotherapy
Polysaccharides
Triple Negative Breast Neoplasms
Salatino, M.
Girotti, M.R.
Rabinovich, G.A.
Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
topic_facet asparagine linked oligosaccharide
epidermal growth factor
glycan
glycogen synthase kinase
transcription factor 4
polysaccharide
programmed death 1 ligand 1
cancer immunotherapy
cytotoxicity
ectopic expression
endocytosis
glycosylation
human
immunosuppressive treatment
lysosome
nonhuman
priority journal
protein protein interaction
Short Survey
treatment response
triple negative breast cancer
tumor microenvironment
tumor rejection
upregulation
immunotherapy
B7-H1 Antigen
Humans
Immunotherapy
Polysaccharides
Triple Negative Breast Neoplasms
description The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. © 2018 Elsevier Inc.
format JOUR
author Salatino, M.
Girotti, M.R.
Rabinovich, G.A.
author_facet Salatino, M.
Girotti, M.R.
Rabinovich, G.A.
author_sort Salatino, M.
title Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_short Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_full Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_fullStr Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_full_unstemmed Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer
title_sort glycans pave the way for immunotherapy in triple-negative breast cancer
url http://hdl.handle.net/20.500.12110/paper_15356108_v33_n2_p155_Salatino
work_keys_str_mv AT salatinom glycanspavethewayforimmunotherapyintriplenegativebreastcancer
AT girottimr glycanspavethewayforimmunotherapyintriplenegativebreastcancer
AT rabinovichga glycanspavethewayforimmunotherapyintriplenegativebreastcancer
_version_ 1807315030635446272